These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 3093387)

  • 41. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Drugs Exp Clin Res; 1987; 13(9):555-61. PubMed ID: 3480796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
    Digranes A; Dibb WL; Benonisen E
    Chemotherapy; 1985; 31(6):466-71. PubMed ID: 2934234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity].
    Marty N; Clave D; Cancet B; Henry-Ferry S; Didier J
    Pathol Biol (Paris); 1988 May; 36(5):460-4. PubMed ID: 3136426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Cullmann W; Stieglitz M; Baars B; Opferkuch W
    Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Resistance against new gyrase inhibitors--1985/86].
    Shah PM; Just G; Weigand G; Stille W
    Dtsch Med Wochenschr; 1987 May; 112(22):903-4. PubMed ID: 3034545
    [No Abstract]   [Full Text] [Related]  

  • 47. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.
    Fass RJ; Helsel VL
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):293-9. PubMed ID: 3107872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro evaluation of E-4695, a new fluoro-naphthyridine.
    Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):188-94. PubMed ID: 1327787
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Symposium on antimicrobial agents. The quinolones.
    Walker RC; Wright AJ
    Mayo Clin Proc; 1987 Nov; 62(11):1007-12. PubMed ID: 3312850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of ethylenediaminetetraacetic acid and gentamicin on the antibacterial activity of pyridone carboxylic acid derivatives against gram-negative bacilli.
    Miyake Y; Mitsui K; Suginaka H
    J Antimicrob Chemother; 1986 Mar; 17(3):327-32. PubMed ID: 3084441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
    Fukuoka Y; Ikeda Y; Yamashiro Y; Takahata M; Todo Y; Narita H
    Antimicrob Agents Chemother; 1993 Mar; 37(3):384-92. PubMed ID: 8460909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.
    Muranaka K; Greenwood D
    J Antimicrob Chemother; 1988 May; 21(5):545-54. PubMed ID: 3134318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates.
    Quentin R; Koubaa N; Cattier B; Gavignet M; Goudeau A
    Antimicrob Agents Chemother; 1988 Jan; 32(1):147-9. PubMed ID: 3258143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
    Nakamura S; Minami A; Nakata K; Kurobe N; Kouno K; Sakaguchi Y; Kashimoto S; Yoshida H; Kojima T; Ohue T
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1167-73. PubMed ID: 2802544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New synthetic quinolone antibacterial agents and serum concentration of theophylline.
    Niki Y; Soejima R; Kawane H; Sumi M; Umeki S
    Chest; 1987 Oct; 92(4):663-9. PubMed ID: 3477409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of amifloxacin (WIN 49,375) compared with those of ciprofloxacin and ofloxacin.
    Digranes A
    Acta Pathol Microbiol Immunol Scand B; 1987 Feb; 95(1):29-32. PubMed ID: 3105246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.